CPRX — Catalyst Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $3.85bn
- $3.10bn
- $588.99m
Italy's Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1 billion
U.S. STOCKS ON THE MOVE-Domino's Pizza, Veradermics, Peloton
Catalyst Pharma gains after report Italy's Angelini exploring acquisition
Brief: Italy’s Angelini Said To Explore Acquisition Of Catalyst Pharma - Bloomberg News
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:03 PM
Brief: Catalyst Pharmaceuticals Inc - District Court Delays Bench Trial To May 18, 2026 - SEC Filing
Catalyst Pharmaceuticals 2025 revenue beats estimates
Brief: Catalyst Pharmaceuticals FY Revenue USD 589 Million Vs. IBES Estimate USD 578.4 Million
Catalyst Pharmaceuticals Q3 revenue beats estimates on FRIDAPSE growth
Brief: Catalyst Pharmaceuticals Q3 Revenue USD 148.4 Million Vs. IBES Estimate USD 136.8 Million
Brief: Catalyst Pharmaceuticals Announces Settlement Of Firdapse® Patent Litigation With Lupin Pharmaceuticals
Brief: Catalyst Pharmaceuticals Announces Settlement Of Firdapse® (Amifampridine) Patent Litigation With Lupin Pharmaceuticals
Catalyst Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Catalyst Pharmaceuticals Q2 Revenue USD 146.6 Million Vs. IBES Estimate USD 140.6 Million
Brief: Catalyst Pharmaceuticals Appoints Daniel Curran, MD, To Its Board Of Directors
Catalyst Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Catalyst Pharmaceuticals Q1 Revenue USD 141.4 Million Vs. IBES Estimate USD 131.5 Million
Brief: Catalyst Pharmaceuticals Announces Health Canada’S Acceptance Of Agamree® New Drug Submission
Catalyst rises on upbeat 2025 revenue forecast, quarterly results beat